Jubilant Pharmova Ltd is an integrated global pharmaceutical company with three core business segments: radiopharmaceuticals, contract development and manufacturing (CDMO), and proprietary novel drugs. The company has a strong presence in the U.S. radiopharma market and operates one of the largest networks of radiopharmacies in North America. Despite its strategic positioning, recent financial performance has been under pressure due to operational challenges, regulatory issues, and weak profitability. This article provides a balanced, fact-based outlook on Jubilant Pharmova’s fundamentals and offers realistic share price targets for each year from 2026 to 2030.
Given negative earnings, low ROCE, and regulatory overhangs, upside is limited unless operational turnaround occurs. Targets assume:
EPS recovery by FY27 post-FDA remediation
P/B compression from 6.7x to 4.5–5.0x over time
Stable dividend policy (~0.5% yield)
Year
Target Price Range (₹)
2026
₹920 – ₹1,020
2027
₹950 – ₹1,080
2028
₹980 – ₹1,150
2029
₹1,010 – ₹1,220
2030
₹1,040 – ₹1,300
⚠️ Note: These are conservative, range-bound targets—not bullish projections. The stock lacks earnings visibility for aggressive re-rating.
Year-wise Breakdown
Jubilant Pharmova Share Price Target 2026
Year
Target 1
Target 2
2026
₹920
₹1,020
Rationale: Q3 FY26 results showed Montreal CDMO facility shut for FDA remediation, impacting margins. Near-term volatility likely, but the radiopharma segment remains resilient.
Jubilant Pharmova Share Price Target 2027
Year
Target 1
Target 2
2027
₹950
₹1,080
Rationale: Expected resumption of CDMO production and cost rationalization could stabilize losses. Radiopharma growth may offset pharma weakness.
Jubilant Pharmova Share Price Target 2028
Year
Target 1
Target 2
2028
₹980
₹1,150
Rationale: If FDA issues are resolved and the R&D pipeline advances, investor sentiment may improve. ROCE needs to exceed 8% for re-rating.
Jubilant Pharmova Share Price Target 2029
Year
Target 1
Target 2
2029
₹1,010
₹1,220
Rationale: Long-term play on U.S. diagnostic imaging demand and aging population. Execution risk remains high.
Jubilant Pharmova Share Price Target 2030
Year
Target 1
Target 2
2030
₹1,040
₹1,300
Rationale: The upper end assumes return to profitability, debt reduction, and market share gains in radiopharma. Even then, valuation remains constrained by an asset-heavy model.
Strengths vs Risks
✅ Strengths
#3 radiopharma player in the U.S. with 46 radiopharmacies
Strong promoter backing (Jubilant Group)
Diversified business model (pharma + CDMO + novel drugs)
Global client base in regulated markets
⚠️ Risks
Negative ROE (0.82%) and ROCE (2.52%) – capital inefficiency
FDA compliance issues (Montreal plant shutdown)
High P/B (6.66x) with no earnings support
Cash reserves are very low (₹12.6 Cr) vs debt (₹306 Cr)
Investment Suitability
Factor
Assessment
Risk Profile
High (turnaround story)
Time Horizon
Long-term (5+ years)
Volatility
Very High
Dividend/Income
Minimal (0.54% yield)
Ideal Investor
Speculative investor betting on FDA resolution and radiopharma leadership; not for conservative portfolios
FAQs
Only for high-risk investors who believe in a full operational turnaround. Not suitable for income or safety-focused investors.
Due to FDA-related shutdowns, weak pharma sales, and high fixed costs in CDMO operations.
It operates in radiopharmaceuticals (diagnostic imaging), CDMO services, and proprietary drug development—with the U.S. as its key market.
No—it carries ₹306.10 Cr in debt with minimal cash buffer (₹12.6 Cr).
A realistic range is ₹920 – ₹1,020, assuming no major regulatory setbacks.
Yes, but minimally—0.54% dividend yield. Payout is maintained despite losses.
Recovery in CDMO operations, expansion in radiopharma, FDA compliance, and potential monetization of its novel drug pipeline.
Final Verdict
Jubilant Pharmova is a high-risk, turnaround candidate with strong niche positioning in radiopharma but severe near-term operational challenges. Its current valuation (P/B 6.66x) is unjustified by fundamentals. The projected 2026–2030 price range (₹920–₹1,300) reflects cautious optimism—contingent on FDA resolution and earnings recovery. Investors should treat this as a speculative bet, not a quality compounder.
📌 Disclaimer: Price targets are estimates based on current data and sector trends. They are not investment advice. Please consult a SEBI-registered advisor.
